Cryoport, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Cryoport provides temperature-controlled supply-chain, logistics, storage, and equipment solutions for life sciences, including biopharma/pharma, animal health, and reproductive medicine. Unless stated otherwise, amounts below are in U.S. dollars.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $62.8 million | $52.3 million | +20.1% |
| Gross profit / gross margin | $27.1 million / 43.1% | $22.3 million / 42.7% | Margin +0.4 percentage points |
| Operating loss | $(10.0) million | $(7.8) million | Loss increased |
| Net loss | $(5.6) million | $(13.4) million | Loss narrowed |
| Net loss attributable to common stockholders | $(7.6) million; $(0.16) per share | $(15.4) million; $(0.31) per share | Loss narrowed |
| Adjusted EBITDA (non-GAAP) | $2.9 million | $2.0 million | Improved |
| Operating cash flow | $2.8 million | $0.5 million | Improved |
- Revenue growth came from both services (+8.9%) and products (+39.1%). The company attributed much of the product-revenue comparison to recovery from the 2022 New Prague facility fire, which it estimated reduced Q1 2022 revenue by approximately $9.4 million. Management also cited demand growth, particularly for commercial cell therapies and in animal health and reproductive medicine.
- By end market, biopharma/pharma revenue was $51.1 million (+18.9%), animal health $8.9 million (+30.4%), and reproductive medicine $2.8 million (+13.4%). Foreign-exchange movements reduced reported revenue by approximately $1.4 million, or 2.3%; revenue at constant currency was $64.3 million, a non-GAAP measure.
- Service gross margin increased to 46.8% from 43.1%; product gross margin declined to 38.2% from 42.0%. Management cited product manufacturing variances and inflation-related costs, partly offset by favorable product mix. SG&A rose 24.9% to $33.2 million, principally reflecting staffing, infrastructure, facilities, stock compensation, and acquisition/integration costs.
- At March 31, cash and cash equivalents were $38.5 million and short-term investments were $484.1 million, or $522.6 million combined. Working capital was $563.1 million. Current assets were $604.6 million against current liabilities of $41.6 million.
- Cash flow from operations was $2.8 million; investing activities used $1.4 million and financing activities provided $0.1 million. Property and equipment purchases were $9.6 million and software development costs were $0.5 million; investment maturities and insurance proceeds partly offset investing outflows.
- Convertible senior notes had $416.8 million aggregate principal outstanding: $402.5 million of 0.75% notes due 2026 and $14.3 million of 3.0% notes due 2025. Their combined balance-sheet carrying value was $407.3 million. Notes payable were $0.4 million. The company also has $20.3 million of Series C preferred stock carrying value and a $2.0 million quarterly paid-in-kind dividend.
Material changes and unusual items
- Net loss improved year over year despite a larger operating loss. The comparison included $4.0 million of other income in Q1 2023 versus $5.0 million of other expense in Q1 2022. Q1 2023 included a $2.6 million gain on the New Prague fire insurance claim and investment-related gains; Q1 2022 included $4.9 million of unrealized losses on equity investments.
- The company received the final $2.2 million insurance payment related to the fire during Q1 2023. Cumulative proceeds through March 31, 2023 were $15.1 million.
- Accumulated other comprehensive loss improved to $29.6 million from $34.5 million, principally reflecting investment-security and foreign-currency translation movements.
- Stock-based compensation was $5.2 million, up from $4.1 million. No shares were repurchased in Q1 2023 under the company’s authorization of up to $100 million through December 2025.
Outlook, risks, and contingencies
- No specific revenue, earnings, or cash-flow guidance is provided in the filing. Management expects continued significant expenses and near-term operating losses while investing in supply-chain initiatives, geographic expansion, and technology. It believes existing cash, investments, and projected cash flows should fund operations and capital requirements for at least 12 months, while noting additional capital may be needed and is not assured on acceptable terms.
- Management identifies risks from supply-chain availability and costs, inflation, labor and transportation constraints, foreign-exchange volatility, COVID-19-related disruption, and the Russia-Ukraine conflict and related sanctions. International operations generated 38% of revenue, and the filing quantifies potential foreign-exchange exposure on cash and intercompany balances.
- A Santa Ana, California facility lease signed in 2022 is scheduled to commence in 2024 and represents $27.7 million of aggregate rent over 10 years; it was not yet included in reported lease assets and liabilities. Existing operating lease liabilities totaled $31.9 million at quarter-end.
- The filing reports no known legal proceeding or claim expected to have a material adverse effect and no defaults under senior securities. It discloses an ongoing Indian tax-authority examination for specified tax periods. No goodwill or intangible-asset impairment was recorded in the quarter.
- Management concluded disclosure controls were effective as of March 31, 2023, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- How much of reported revenue growth reflects underlying demand versus recovery from the New Prague fire comparison, acquisitions, and foreign-exchange effects.
- Whether product-margin pressure from manufacturing variances, inflation, and safety-stock levels persists, and whether operating expenses scale with revenue.
- The quality and liquidity of the $484.1 million short-term investment portfolio, including interest-rate sensitivity and unrealized losses; management says it does not expect to sell loss-position securities before recovery.
- Cash requirements for planned investments and the future Santa Ana lease, alongside the 2025 and 2026 convertible-note maturities, terms, and potential dilution. The company disclosed approximately 17.9 million shares reserved for future issuance through awards and conversions.
- Whether management’s stated 12-month liquidity assessment remains supportable as operating losses and capital needs evolve; adjusted EBITDA is non-GAAP and should be considered with GAAP results and cash flow.